Invesco Ltd. Has $840.06 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Invesco Ltd. increased its stake in Thermo Fisher Scientific Inc. by 0.6%, holding 1,688,214 shares valued at approximately $840 million after purchasing an additional 10,633 shares in the first quarter.
• Several institutional investors are actively buying shares of Thermo Fisher, with 89.23% of the stock owned by institutions, highlighting strong institutional interest in the company.
• Thermo Fisher recently announced a quarterly dividend of $0.43 per share, which will be payable on October 15th, indicating ongoing shareholder returns amidst stable financial performance.

Invesco Ltd. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,688,214 shares of the medical research company's stock after purchasing an additional 10,633 shares during the period. Invesco Ltd. owned 0.45% of Thermo Fisher Scientific worth $840,055,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $35,000. Navigoe LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Thermo Fisher Scientific during the first quarter valued at about $37,000. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,400 shares of company stock valued at $8,345,792. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Barclays raised their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Evercore ISI cut their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Robert W. Baird raised their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Stock Up 1.5%

TMO opened at $461.34 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a 50-day simple moving average of $426.80 and a two-hundred day simple moving average of $463.40. The company has a market capitalization of $174.21 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.46 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm earned $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.